| |
| |
|
| Insider
Information: |
Harris Erik |
| Relationship: |
Director |
| City: |
Novato |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
78,248 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$3,087,292 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
78,248 |
|
|
| Total
Value |
$3,087,292 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ultragenyx Pharmaceutical Inc |
RARE |
|
2024-03-01 |
67,163 |
2019-06-19 |
0 |
Premium* |
|
|
Denali Therapeutics Inc. |
DNLI |
Director |
2023-06-01 |
11,085 |
2022-02-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2024-03-01 |
4 |
S |
$53.76 |
$256,328 |
D/D |
(4,768) |
67,163 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
20,357 |
71,638 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2023-09-05 |
4 |
S |
$37.96 |
$227,760 |
D/D |
(6,000) |
51,281 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2023-06-19 |
4 |
S |
$48.20 |
$14,701 |
D/D |
(305) |
57,281 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,216 |
11,085 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2023-03-01 |
4 |
S |
$45.25 |
$165,796 |
D/D |
(3,664) |
57,344 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
24,663 |
60,823 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2022-06-19 |
4 |
S |
$54.78 |
$16,160 |
D/D |
(295) |
36,160 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2022-03-01 |
4 |
S |
$66.62 |
$180,740 |
D/D |
(2,713) |
22,317 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
36,317 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,869 |
6,869 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2021-10-14 |
4 |
S |
$81.14 |
$24,585 |
D/D |
(303) |
25,030 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2021-07-06 |
4 |
S |
$91.53 |
$34,324 |
D/D |
(375) |
25,333 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2021-06-21 |
4 |
AS |
$94.96 |
$54,317 |
D/D |
(572) |
25,708 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2021-06-19 |
4 |
AS |
$94.63 |
$41,353 |
D/D |
(437) |
26,280 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2021-05-07 |
4 |
AS |
$113.67 |
$44,672 |
D/D |
(393) |
26,717 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2021-05-06 |
4 |
AS |
$113.68 |
$34,900 |
D/D |
(307) |
27,110 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2021-04-20 |
4 |
AS |
$104.28 |
$41,295 |
D/D |
(396) |
27,417 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2021-03-02 |
4 |
AS |
$138.16 |
$97,679 |
D/D |
(707) |
27,813 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2021-03-01 |
4 |
AS |
$138.17 |
$341,280 |
D/D |
(2,470) |
28,520 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,136 |
30,990 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2020-10-14 |
4 |
S |
$88.00 |
$19,360 |
D/D |
(220) |
23,370 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2020-07-06 |
4 |
D |
$86.75 |
$22,555 |
D/D |
(260) |
23,590 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2020-06-19 |
4 |
D |
$78.22 |
$23,701 |
D/D |
(303) |
23,850 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
EVP & Chief Commercial Officer |
• – – |
2020-06-03 |
4 |
S |
$74.69 |
$187,920 |
D/D |
(2,516) |
20,854 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
